Antibiotics: New substances break bacterial resistance

Whether staphylococcus or the dreaded MRSA germs: resistant bacteria are a problem for physicians and patients worldwide. Only a few weeks ago, several large pharmaceutical companies also announced that they were further cutting back their own research work on new antibiotics.

“However, in order to be able to treat infectious diseases reliably and in the long run, we need new active substances against which bacteria have not yet developed resistances,” says Professor Andreas Hilgeroth from the Institute of Pharmacy at MLU.

Together with researchers from the University of Greifswald and the Julius Maximilian University of Würzburg, he is working on these new active substances in a research project funded by the Federal Ministry of Education and Research.

The scientists have developed new active ingredients that attack a special enzyme that only appears in this form in pathogenic bacteria: the so-called pyruvate kinase. It plays an important role in metabolic processes.

The idea: If the metabolism of the bacteria is obstructed, this ultimately renders them harmless. “The pyruvate kinase is an ideal target for new active ingredients. In the best case, the new substances only affect the bacterial enzyme and therefore the bacteria. If so, there should be only a few side effects. In addition, this new target structure can be used to break existing antibiotic resistance,” Hilgeroth continues.

In cell experiments and initial tests on the larvae of the greater wax moth, a model organism used in life sciences, the researchers were able to confirm the efficacy of their new substances. The best compounds achieved at least as good results as conventional antibiotics. A patent application has also been filed for these active ingredients.

“These initial results give us confidence that we are on the right track,” Hilgeroth says. However, the ingredients still have to undergo numerous other tests before they can be tested in large-scale clinical trials on humans. Thus it may take more than ten years before the substances of the scientists from Halle, Würzburg and Greifswald become a marketable drug.

Professor Andreas Hilgeroth
Institute of Pharmacy
phone: +49 345 55-25168
mail: andreas.hilgeroth@pharmazie.uni-halle.de

Seethaler M. et al. Novel small-molecule antibacterials against Gram-positive pathogens of Staphylococcus and Enterococcus species. Antibiotics (2019). https://doi.org/10.3390/antibiotics8040210

Media Contact

Ronja Münch idw - Informationsdienst Wissenschaft

All latest news from the category: Life Sciences and Chemistry

Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.

Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.

Back to home

Comments (0)

Write a comment

Newest articles

New Milestone in Quantum Research

Google Quantum AI and quantum physicists at Freie Universität Berlin publish groundbreaking results on Hamiltonian operators. A research team including researchers at Freie Universität Berlin and Google Quantum AI has…

Breakthrough in photonic time crystals

… could change how we use and control light. The new discovery could dramatically enhance technologies like lasers, sensors and optical computing in the near future. An international research team…

Custom Print Heads for 3D Printing

Achieving Individual Functional Integration. Wire or Fiber Encapsulating Additive Manufacturing (WEAM/FEAM) could significantly simplify the industrial production of components that require the integration of complex yet compact wiring, sensors, actuators,…